Screening for trisomy 21 in Flanders: A 10 years review of 40.490 pregnancies screened by maternal serum

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 115, Issue 2, 2004, Pages 185-189

  Gyselaers, Wilfried J A ^a   Vereecken, Annie J ^b   Van Herck, Eric J H ^b   Straetmans, Dany P L ^b   Martens, Guy E I ^c   De Jonge, Eric T M ^a   Ombelet, Willem U A M ^a   Nijhuis, Jan G ^d  

^a DEPARTMENT OF CARDIOLOGY   (Belgium)

^b Algemeen Medisch Laboratorium   (Belgium)

^c Studiecentrum voor Perinatale Epidemiologie   (Belgium)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Advanced maternal age; Antenatal invasive procedures; Second trimester screening; Sequential screening; Trisomy 21

Indexed keywords

ADULT; CONTROLLED STUDY; DATA BASE; EMBRYO; FEMALE; FETUS; FETUS ECHOGRAPHY; HUMAN; MATERNAL AGE; MATERNAL SERUM; PREGNANCY; PRIORITY JOURNAL; REVIEW; SCREENING; SECOND TRIMESTER PREGNANCY; TRISOMY 21;

EID: 3242739225     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2003.12.014     Document Type: Article

References (22)

1. Nicolaides K.H. Screening for chromosomal defects. Ultrasound Obstet. Gynecol. 21:2003;313-321
2. Cuckle H. Integrating antenatal Down's syndrome screening. Curr. Opin. Obstet. Gynecol. 13:2001;175-181
3. Benn P. Improved antenatal screening for Down's syndrome. Lancet. 361:2003;794-795
4. Eurocat Website Database, Eurocat University of Ulster, 2003, http://www.eurocat.ulster.ac.uk.
5. Snijders R.J., Noble P., Sebire N., Souka A., Nicolaides K.H. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet. 352:1998;343-346
6. Witters I. Prenatal Diagnosis of Fetal Malformations and Chromosomal Anomalies: A Multidisciplinary Approach (Thesis), Catholic University, Louvain, 2002, p. 7-158.
7. Wenstrom K.D., Desai R., Owen J., DuBard M.B., Boots L. Comparison of multiple-marker screening with amniocentesis for the detection of fetal aneuploidy in women > or = 35 years old. Am. J. Obstet. Gynecol. 173:1995;1287-1292
8. Abramowicz MJ, Reynolds T, Vamos E, Zimmermann R. Screening for chromosome and genetic abnormalities. In: Kurjac A, editor. Textbook of perinatal medicine: a comprehensive guide to modern clinical perinatology. London: Parthenon Publishing Group Ltd. p. 610-637.
9. Wald N.J., Kennard A., Hackshaw A., McGuire A. Antenatal screening for Down's syndrome. J. Med. Screen. 4:1997;181-246
10. Haddow J.E., Palomaki G.E., Knight G.J., Cunningham G.C., Lustig L.S., Boyd P.A. Reducing the need for amniocentesis in women 35 years of age or older with serum markers for screening. N. Engl. J. Med. 330:1994;1114-1118
11. Dommergues M., Audibert F., Benattar C., Champagne C., Gomel V., Frydman R. Is routine amniocentesis for advanced maternal age still indicated? Fetal Diagn. Ther. 16:2001;372-377
12. Audibert F., Mairovitz V., Frydman R. Alternatives to amniocentesis for maternal age. Gynecol. Obstet. Fertil. 30:2002;562-566
13. Reynolds T.M., Nix A.B., Dunstan F.D., Dawson A.J. Age-specific detection and false-positive rates: an aid to counseling in Down's syndrome risk screening. Obstet. Gynecol. 81:1993;447-450
14. Cavalli P., Gnocchi E., Pennacchio A., Morrica B. Dual analyte screening for fetal Down's syndrome in pregnant women over 35 years of age. Prenat. Diagn. 18:1998;637-638
15. Muller F., Forestier F., Dingeon B. Second trimester trisomy 21 maternal serum marker screening. Results of a countrywide study of 854,902 patients. Prenat. Diagn. 22:2002;925-929
16. Zoppi M.A., Ibba R.M., Floris M., Monni G. Fetal nuchal translucency screening in 12,495 pregnancies in Sardinia. Ultrasound Obstet. Gynecol. 18:2001;649-651
17. Krantz D.A., Hallahan T.W., Orlandi F., Buchanan P., Larsen J.W. Jr., Macri J.N. First-trimester Down's syndrome screening using dried blood biochemistry and nuchal translucency. Obstet. Gynecol. 96:2000;207-213
18. Spencer K., Spencer C.E., Power M., Moakes A., Nicolaides K.H. One stop clinic for assessment of risk for fetal anomalies: a report of the first year of prospective screening for chromosomal anomalies in the first trimester. Br. J. Obstet. Gynecol. 107:2000;1271-1275
19. Thilaganathan B., Slack A., Wathen N.C. Effect of first-trimester nuchal translucency on second-trimester maternal serum biochemical screening for Down's syndrome. Ultrasound Obstet. Gynecol. 10:1997;261-264
20. Kadir R.A., Economides D.L. The effect of nuchal translucency measurement on second-trimester biochemical screening for Down's syndrome. Ultrasound Obstet. Gynecol. 9:1997;244-247
21. Hackshaw A.K., Wald N.J. Inaccurate estimation of risk in second trimester serum screening for Down's syndrome among women who have already had first trimester screening. Prenat. Diagn. 21:2001;741-746
22. Cuckle H. Time for total shift to first-trimester screening for Down's syndrome. Lancet. 358:2001;1658-1659